Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 5/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31132796 | 0.79 | CYP11B1 (0.58) | LMNATDP1CDK8CYP11B1CYP11B2 | |
| SCHEMBL4470790 | 0.79 | CYP11B1 (0.58) | LMNATDP1CDK8CYP11B1CYP11B2 | |
| SCHEMBL7926561 | 0.77 | ABL1 (0.41) | CDK8DYRK1ADYRK1BABL1LTA4H | |
| SCHEMBL8736575 | 0.75 | LMNA (0.67) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL24155608 | 0.74 | DYRK1A (0.50) | LMNATDP1DYRK1ADYRK1BCYP11B1 | |
| SCHEMBL2305750 | 0.74 | IL2 (0.56) | LMNAABL1 | |
| SCHEMBL30072834 | 0.74 | LMNA (0.61) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL4799691 | 0.74 | LMNA (0.61) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL13838573 | 0.72 | ABL1 (0.39) | CDK8ABL1LTA4H | |
| SCHEMBL3813230 | 0.72 | ABL1 (0.63) | DYRK1ADYRK1BCYP11B1CYP11B2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | LMNA 4714/4885TDP1 3322/4885CDK8 1525/4885 |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | LMNA 4714/4885TDP1 3322/4885CDK8 1525/4885 |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | LMNA 4714/4885TDP1 3322/4885CDK8 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.